Download ACCRU MC Cancer Research Consortium Newsletter

Connections
Vol. 6 No. 1 Spring 2016
Inside this issue
New Board of Directors
members...................................2
Meeting news............................3
– Spring ACCRU Scientific
Program Overview
– ACCRU to exhibit at ASCO
Membership news.....................3
– Top accruing members
– ACCRU welcomes new members
– How to submit study concepts
to ACCRU
– Membership profile: National
University Cancer Institute,
Singapore
Trial highlights...........................6
– ACCRU trial for lung cancer
approaching accrual goal
– New trial evaluates the utility
of topical cryotherapy
– New trial examines treatment for
metastatic colorectal cancer
Operations updates..................11
– New business management system
– Personnel update
– Membership survey
– ACCRU Research Coordinating
Center staff
Message from the chair
New COO and
board members
This past December,
we said farewell
to Aimee Tillman,
who has served
Axel Grothey, M.D.
as ACCRU’s chief
operations officer
since 2011. She previously served in
this role for the Mayo Clinic Cancer
Research Consortium, ACCRU’s
predecessor, starting in 2005.
Aimee was
instrumental in
establishing ACCRU
as a successful
clinical trials network
with national and
international reach.
Aimee Tillman
Please join me in
thanking Aimee for
her outstanding service and wishing
her the best of luck in her new position
as director of Eye Services for Mayo
Clinic Health System in La Crosse,
Wisconsin.
We welcome Elizabeth (Beth) Kiefer
as our new chief operations officer for
ACCRU. Beth has been
with the Mayo Clinic
Cancer Center since
2010, serving as the
operations manager
for the Systems
Management Office
Beth Kiefer
with a strong presence
for the Alliance and
Alliance Foundation. She
brings to ACCRU a wealth of experience
in systems and process improvement,
and great insights into the needs of
clinical trial networks. For the past five
years, Beth has partnered with ACCRU to
provide electronic case report forms and
information technology support. Please
join me in welcoming Beth to her new role
with ACCRU.
We also welcome two new members
of our Board of Directors – Minetta Liu,
M.D., and Tanios Bekaii-Saab, M.D. Their
expertise will prove invaluable as we
expand our scientific efforts (see article on
page 2).
Supporting our members
Our goal is to provide our members with
outstanding support for their clinical
continued on next page
Academic and community investigators partner to develop new cancer therapies
continued from previous page
research participation. We are excited
about a new web-based application called
ACCRU Business Management System
(ABMS) that we implemented in February
to enhance our clinical trial administration
capabilities. The new system automates
many of our operations, allowing us
to gather information about each
membership and identifying disease areas
where there is a demand for clinical trials
(see article on page 11).
University Cancer Institute, Singapore, a
group which focuses research on cancers
endemic to its region (see article on page 4).
We value our members’ input and
encourage each membership to complete
our upcoming membership survey. It will
help us identify additional information and
services that will assist you in your clinical
research efforts with ACCRU (see article
on page 5).
We thank you for your continued support
and hope to see you at the upcoming
ACCRU Scientific Program Overview on
May 14 in Chicago and at our American
Society of Clinical Oncology booth in
Chicago from June 4 to 7 (see article on
page 2 for more information on these
meetings).
New members and upcoming trials
Axel Grothey, M.D.
ACCRU chair
ACCRU offers investigators a unique
opportunity to bring clinical research
ideas forward that may otherwise not be
possible. In this issue, we highlight three
trials that are exploring new treatment
or symptom control options (see trial
highlights beginning on page 6).
We continue to welcome new members to
our growing network, including National
New Board of Directors members
We welcome two new Mayo Clinic representatives to the
ACCRU Board of Directors. They are Minetta C. Liu, M.D.,
an oncologist at Mayo Clinic’s campus in Rochester, Minn.,
and Tanios Bekaii-Saab, M.D., an oncologist who will join
Mayo Clinic’s campus in Arizona on May 23.
Dr. Liu specializes in breast cancer, and Dr. Bekaii-Saab,
currently section chief for Gastrointestinal (GI) Oncology
and associate professor of Internal Medicine and
Pharmacy at The Ohio State University, also serves as
co-chair of the ACCRU GI Disease Committee.
We also wish to thank two retiring board members –
Edith A. Perez, M.D., an oncologist at Mayo Clinic’s
campus in Jacksonville, Fla., and Charles Erlichman, M.D.,
an oncologist at Mayo Clinic’s campus in Rochester, Minn.
– for their commitment and outstanding service to ACCRU.
2 ACCRU Connections | Spring 2016
Minetta C. Liu, M.D.
Tanios Bekaii-Saab, M.D.
Edith A. Perez, M.D.
Charles Erlichman, M.D.
Meeting news
Spring ACCRU Scientific Program
Overview
Join us for the spring ACCRU Scientific Program
Overview meeting on Saturday, May 14, at the
Loews Chicago O’Hare Hotel in Rosemont, Ill.
Please note this meeting is not included on the
Alliance for Clinical Trials in Oncology agenda.
No registration is required and all Alliance
members are welcome to attend. We look
forward to seeing you there.
ACCRU to exhibit at American Society of
Clinical Oncology (ASCO) 2016
Visit ACCRU (booth #2039) at the American
Society of Clinical Oncology (ASCO) meeting
from Saturday, June 4, to Monday, June 7, 2016,
9 a.m. to 5 p.m., at McCormick Place in Chicago.
Membership news
Top accruing member sites
We would like to recognize and thank the following
ACCRU memberships, which are the top sites for
patient accrual to date for 2016:
Academic memberships
• Mayo Clinic, Rochester, Minn.
• Duke University Medical Center, Durham, N.C.
• The Ohio State University Wexner Medical
Center, Columbus
Community memberships
• Illinois CancerCare, Peoria
• New Hampshire Oncology-Hematology,
PA, Hooksett
• Rapid City Regional Hospital, S.D.
Meet ACCRU investigators and staff, and learn
about current ACCRU trials, how to bring a
study forward in ACCRU and our network’s
capabilities.
ACCRU welcomes new members
For more information on the ASCO meeting, visit
http://am.asco.org/.
• AnMed Health Cancer Center,
Anderson, S.C.
The ACCRU leadership would like to extend
a warm welcome to our newest members:
• Allegheny Singer Research Institute,
Pittsburgh, Pa.
• Waverly Hematology Oncology,
Cary, N.C.
• Vassar Brothers Medical Center,
Poughkeepsie, N. Y.
• Maine Center for Cancer Medicine and
Blood Disorders, Scarborough
3 ACCRU Connections | Spring 2016
How to submit study concepts to ACCRU
We encourage all members to bring study concepts forward for consideration by
ACCRU. Here are answers to your frequently asked questions about the study concept
submission process.
Who can submit concepts?
Any ACCRU investigator can bring a protocol, concept, or letter of intent (LOI) forward for
consideration.
What types of trials does ACCRU conduct?
ACCRU accepts concepts for investigator-written or industry-sponsored clinical trials.
We offer a broad range of clinical trials for many types of cancer and conduct phase II,
phase III and biosimilar trials as well as expanded access programs.
What information needs to be submitted?
Provide information on:
• The protocol, concept or LOI
• Mechanism for funding the trial
What support does ACCRU offer?
• Concept/protocol review by key opinion leaders
• All clinical trial administrative services, including protocol development, regulatory
document and data management and operations and statistical support
• Biospecimen repository and correlative laboratory services
Who do I contact to submit a study concept?
Contact the ACCRU Research Coordinating Center by email at [email protected] or by
phone at 507-538-7448.
Membership profile
National University Cancer Institute, Singapore joins ACCRU
We are excited to welcome National
University Cancer Institute, Singapore
(NCIS) as a new member of ACCRU.
NCIS is a national specialist center
under the National University Health
System (NUHS). It is the only public
cancer center in Singapore treating both
pediatric and adult cancers in one facility.
Cancer is the most common cause
of death in Singapore, with colorectal
cancer being the most common cancer. The goal of NCIS is to provide comprehensive,
personalized care – from cancer awareness and prevention to diagnosis and treatment
– through multidisciplinary tumor groups for every patient, complemented by long-term
supportive care.
Cheng Ean Chee, M.D.
4 ACCRU Connections | Spring 2016
Rachel Lim
continued on next page
continued from previous page
Cheng Ean Chee, M.D., assistant professor at the Yong Loo Lin School of Medicine,
Singapore, and a gastrointestinal oncologist at NCIS, is the principal investigator for ACCRU.
She is also part of the Developmental Therapeutics group at NCIS. After completing her
Hematology-Oncology fellowship at Mayo Clinic, she joined the Hematology and Oncology
Division at Case Western Reserve University in Cleveland, Ohio, before moving to Singapore
in 2014. Rachel Lim at NCIS is the primary clinical research associate for ACCRU.
“Along with our involvement in more regional and global clinical trials, our membership
with ACCRU will raise our visibility and enable us to become a global center for cancer
treatment and research,” says Dr. Chee. “We will also gain recognition by the international
academic community and industry. We hope to contribute investigator-initiated studies
to ACCRU, especially in cancers endemic to our region, such as stomach, liver, lung and
nasopharyngeal cancers.”
Focus on cancers endemic to Asia
The Hematology-Oncology Research Group (HORG) is the research arm of NCIS. Comprised
of committed hematologists and oncologists, the HORG team strives to provide the best
treatment options and care for patients through continuous research of cancers endemic
to Asia. HORG is part of the Cancer Therapeutics Research Group (CTRG), an Asia-Pacific
medical oncology cooperative cancer research group that includes member institutions from
Singapore, Australia, Hong Kong, Korea and Taiwan.
Through its membership in CTRG, NCIS has participated in the Mayo Clinic Phase 2
Consortium, which provides access to novel compounds offered through the National Cancer
Institute – Cancer Therapy Evaluation Program for proof-of-concept studies. NCIS also
participates in the Breast International Group in Belgium.
NCIS works closely with scientists from the Cancer Science Institute (CSI) of Singapore, a
national research center of excellence, and the National University of Singapore (NUS). CSI
Singapore conducts basic and translational cancer studies through their Cancer Stem Cell
and Biology and Experimental Therapeutics research programs. Areas of focus lie particularly
in gastric, liver, lung and leukemia cancers, which are prevalent in Asian populations, along
with a breast cancer working group examining Asian phenotypes.
There is a full spectrum of basic and clinical translational facilities with a multitude of stateof-the-art core support technologies. For translational research in clinical imaging, NCIS
collaborates with the Clinical Imaging Research Center at NUS, the first center in Southeast
Asia to use the latest imaging technologies such as MRI/PET scanners.
Developmental Therapeutics Unit
Given the lack of Asian patients recruited to phase I trials, which are generally conducted
in western countries, NCIS recognized the need to establish a phase I unit that would
specifically address the question of identifying optimal drug doses in Asian patients. In
the area of pharmacogenetics, HORG is one of several global teams studying inter-ethnic
variability in anti-cancer drugs. The establishment of NCIS Developmental Therapeutics
Unit has already helped attract interest from drug companies seeking academic partners
who have the appropriate infrastructure to support early phase clinical trials in Asia. These
research efforts have enabled NCIS to provide its patients access to cutting-edge therapies.
5 ACCRU Connections | Spring 2016
Trial profiles
ACCRU trial for lung cancer approaching accrual goal
ACCRU trial RC1126 is a randomized phase II trial investigating
erlotinib with and without bevacizumab in patients with stage IV
non-small cell lung cancer (NSCLC) with an activating mutation
of the epidermal growth factor receptor (EGFR). Thomas
Stinchcombe, M.D., at the University of North Carolina, is the
principal investigator for the study. Currently, 74 of the planned
86 patients have been enrolled.
“Single agent erlotinib is currently approved for treatment of
patients with EGFR mutant NSCLC,” says Dr. Stinchcombe. “The
Thomas Stinchcombe, M.D.
hope is that the combination of erlotinib and bevacizumab will
improve outcomes for patients with stage IV NSCLC.”
Background
Patients with an EGFR mutation, defined as an exon 19 mutation and exon 21 L858R
point mutation, receive an EGFR tyrosine kinase inhibitor, which results in a high
response and long progression-free survival. However, patients inevitably develop
progressive disease, generally within 10 to 12 months of starting therapy.
Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor
and inhibits the growth of new blood vessels, which are critical for cancer growth and
metastases. Bevacizumab is approved for use in advanced NSCLC in combination with
carboplatin and paclitaxel chemotherapy.
A previous trial compared erlotinib to erlotinib and bevacizumab in patients who had
progressive disease after chemotherapy. In this trial, a subset of 30 patients had an EGFR
mutation, and patients who received erlotinib and bevacizumab compared to erlotinib
alone had a longer progression-free survival.
In Japan, a trial of similar design to RC1126 investigated the combination of erlotinib and
bevacizumab compared to erlotinib alone specifically in patients with an EGFR mutation.
This trial revealed that patients assigned to the combination had a statistically significant
longer progression-free survival with acceptable toxicity.
Study objectives
The primary objective of this study is to compare the progression-free survival of erlotinib
with bevacizumab compared to erlotinib alone. The secondary objectives are to assess
the objective response rate, overall survival and safety of each treatment arm, and to
explore if type of mutation (exon 19 versus exon 21 L858R) is associated with benefit. The
correlative science studies will investigate the molecular mechanisms of resistance.
6 ACCRU Connections | Spring 2016
New trial evaluates the utility of topical cryotherapy
In December 2015, ACCRU opened a randomized, controlled
clinical trial evaluating the effectiveness of topical cryotherapy
to decrease chemotherapy-induced peripheral neuropathy and
paclitaxel-induced acute pain syndrome. The pilot clinical trial
is expected to enroll 46 patients. Charles L. Loprinzi, M.D., an
oncologist at Mayo Clinic’s campus in Rochester, Minn., and vice
chair of ACCRU, is the study chair.
”There is a considerable amount of anecdotal information and
a couple of reports that support the use of topical cryotherapy
Charles L. Loprinzi, M.D.
to decrease paclitaxel-induced neuropathy,” says Dr. Loprinzi.
“Nonetheless, prospective controlled data is necessary to better understand the efficacy
and tolerability of this approach.”
Background
Paclitaxel, one of the more widely used chemotherapy agents in the treatment of
cancer, can cause peripheral numbness, tingling and pain, usually starting in the
hands and feet. These symptoms begin in the first weeks of therapy and become
more prominent over time with continued drug use. After paclitaxel is discontinued,
symptoms tend to improve over time. These symptoms are related to nerve pathology
and are called chemotherapy-induced peripheral neuropathy, which is also caused by
other neurotoxic chemotherapy agents.
For a majority of patients, paclitaxel also causes a syndrome of subacute aches and
pains that had been commonly referred to as arthralgias and myalgias. In studies to
further identify the cause and nature of these symptoms, patients commonly described
the discomfort as “aching” or “deep pain” that was “radiating,” “stabbing,” or “shooting.”
The pain was usually generalized and located in the back, hips, shoulders, thighs, legs
and feet and, at times, radiated down the legs, arms or back. Researchers concluded
that the subacute paclitaxel-induced pain appeared to be related to a pathologic process
in nerve tissue, such as sensitization of nociceptors or nociceptive fibers, as opposed to
being from a musculoskeletal injury.
Because both of these paclitaxel toxicity syndromes appear to be related to nerve
pathology, researchers have studied agents that treat neuropathic pain as a method for
preventing and treating these problems.
A recent review article, Supportive cryotherapy: a review from head to toe, details the
history of cryotherapy as a part of the management of patients with cancer (Kadakia et
al., 2014). Cryotherapy was initially reported to be helpful for decreasing Adriamycininduced alopecia, with initial studies dating back to the 1970s.
There has been a recent resurgence of this approach with newer methods of providing
scalp cryotherapy. In addition, oral cryotherapy was first reported to be helpful for
preventing 5-fluorouracil-induced mucositis in 1991 in a manuscript published by the
7 ACCRU Connections | Spring 2016
continued from previous page
North Central Cancer Treatment Group. It is now recommended for clinical use by the
Multinational Association of Supportive Care in Cancer mucositis guidelines following
multiple confirmatory trials. Cryotherapy has also been reported to be beneficial for
decreasing 5-fluorouracil-induced ocular toxicity, and it has been shown to decrease
chemotherapy-induced onycholysis (Matsumoto 2009).
Some past studies may explain how cryotherapy decreases peripheral neuropathy. Study
results demonstrate that patients receiving paclitaxel lose epithelial nerve fibers (Ko et al.,
2014, Boyette-Davis et al., 2013, and Bennett et al., 2011). This may occur because of a
local reaction from chemotherapy getting to the distal epithelial nerve fibers. Cryotherapy
should cause vasoconstriction and decrease the amount of paclitaxel getting to the distal
epithelial nerve fibers, thus resulting in decreased neuropathy.
A potential concern regarding the use of cryotherapy is that paclitaxel has a reported
half-life of about five hours (Gianni et al., 1995). Given this, it would seem that decreasing
blood flow during the time of chemotherapy administration would not have much
effect. However, docetaxel has a terminal half-life of 13.5 hours (Extra et al., 1993), yet
cryotherapy has repeatedly been shown to decrease nail toxicity (Kadakia et al., 2014).
Additionally, Adriamycin has a reported half-life of 30 hours (Benjamin et al., 1977),
yet scalp cryotherapy can decrease alopecia when only given for a couple of hours
(Kadakia et al., 2014). In all three of these situations, it may be that the cryotherapy
decreases blood flow to target tissues when there are peak drug concentrations in the
plasma, and this decreases the toxicity.
The above data support further evaluation of cryotherapy as a means to prevent
paclitaxel-associated neuropathy. Pilot study data are needed prior to conducting a
larger phase III, more definitive trial. The data from the ACCRU trial will provide an
estimate of the amount of potential benefit from this approach.
Study objectives
Trial objectives include:
• To estimate whether topical cryotherapy can alleviate chemotherapy-induced
peripheral neuropathy
• To estimate whether topical cryotherapy can alleviate paclitaxel-induced
peripheral neuropathy
• To examine the possible relative toxicities related to topical cryotherapy in this
study situation
For further information
For further information on ACCRU trial RU221511I, contact Michelle (Shelly)
Hewlett, research protocol specialist at the ACCRU Research Coordinating
Center, at [email protected].
8 ACCRU Connections | Spring 2016
New trial examines treatment for metastatic colorectal cancer
In second quarter 2016, ACCRU will
activate an open label, randomized
phase II study of nintedanib alone or
in combination with capecitabine for
patients with refractory metastatic
colorectal cancer. Clinical trial
BI1199.251 is sponsored by Boehringer
Ingelheim Pharmaceuticals, Inc. Arvind
Dasari, M.B.B.S., assistant professor,
Gastrointestinal Medical Oncology at
Arvind Dasari, M.B.B.S.
Axel Grothey, M.D.
The University of Texas MD Anderson
Cancer Center, in Houston is principal investigator for the trial. Axel Grothey, M.D.,
an oncologist at Mayo Clinic in Rochester, Minn., and ACCRU chair, is the principal
investigator for the trial. The trial is expected to enroll 100 patients.
“The results of this trial, if favorable, will lead the way to further development and
integration of nintedanib in the therapy for metastatic colon cancer,” says Dr. Dasari.
“Given the excellent tolerance of nintedanib, we are hoping these efforts will eventually
lead to improved survival of our patients with minimal impact on their quality of life.”
“This trial will investigate the activity of an exciting novel agent, nintedanib, in
combination with capecitabine in patients with pretreated advanced colorectal
cancers,” adds Dr. Grothey. “If active, this combination regimen could be integrated
into earlier lines of therapy for this malignancy in future studies.”
Background
Colorectal cancer has a high incidence, with approximately 1.4 million new cases per
year worldwide and approximately 132,000 new cases per year in the U.S. In addition,
it is the second leading cause of cancer-related deaths in western countries. Most of
the newly diagnosed patients initially undergo surgery and receive adjuvant systemic
treatment. However, 25 to 35 percent of patients eventually develop metastatic disease
in addition to the 15 to 25 percent of patients presenting with metastatic disease at the
time of diagnosis.
Patients with metastatic colorectal cancer have a large unmet medical need. Treatment
options for these patients are restricted due to the efficacy and toxicity of available
treatments. While there are reported clinical advances in the treatment of metastatic
colorectal cancer by using a combination of chemotherapy and targeted therapies,
there is additional need for more effective and tolerable agents for these patients.
In metastatic colorectal cancer, as well as in other types of cancer, the combination of
chemotherapy and anti-angiogenic therapies has been shown to provide bene¬ t. In
addition, preclinical and observational studies indicate that vascular endothelial growth
factor (VEGF) inhibition, when sustained by administering bevacizumab, is bene¬ficial
in some patients with solid tumors. Also preclinical data suggest that continued VEGF
inhibition leads to achieving and maintaining tumor regression.
9 ACCRU Connections | Spring 2016
continued from previous page
Studies have also shown that the combination of 5FU/capecitabine chemotherapy and
bevacizumab as an anti-angiogenic complement each other. For patients with metastatic
colorectal cancer, continuation of VEGF inhibition after first disease progression was
associated with significant prolonged overall survival.
Nintedanib use, instead of bevacizumab, in combination with a fluoropyrimidine, may be
associated with less frequent hospital visits since it is an oral therapy and does not require
intravenous administration.
Van Cutsem et al. reported on a 128-patient randomized phase I-II trial that evaluated
nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in ¬ first-line treatment
and mFOLFOX6 showed efficacy as first-line therapy in patients with metastatic colorectal
cancer and offered a manageable safety pro¬ le. Investigators concluded that further studies
in this population are warranted.
Clinical trial BI1199.251 will investigate the ef¬ficacy and safety of nintedanib alone or in
combination with capecitabine for patients with refractory metastatic colorectal cancer
after failure of at least two lines of standard treatment. The outcome of this study should
be informative for future trials to investigate this dual oral combination therapy in the
maintenance setting after primary chemotherapy induction.
Study objectives
Trial objectives include:
• The primary objective is to assess progression-free survival in patients with refractory
metastatic colorectal cancer, treated with nintedanib alone or in combination with
capecitabine.
• The secondary objectives are to assess overall survival, objective response, disease
control and safety for both treatment arms.
For further information
For further information on clinical trial BI1199.251, contact Danielle Davis,
research protocol specialist at the ACCRU Research Coordinating Center, at
[email protected].
10 ACCRU Connections | Spring 2016
Operations updates
New business management system offers streamlined processes for members
In February 2016, ACCRU implemented a new web-based application called ACCRU Business
Management System (ABMS) to enhance our clinical trial administration capabilities. Over the
course of the year, members will be using the application for several administrative tasks.
The new system features a Site Profile section that enables us to gather information about each
membership, including staff, patient population and facility capabilities.
In addition, members will now use the system to complete online feasibility forms. These
automated forms enable ACCRU to more efficiently access feasibility data for each membership
and identify potential sites for ACCRU studies.
Members can contact the ACCRU Research Coordinating Center by email at ACCRU@mayo.
edu or by phone at 507-538-7448 with questions about the new system or suggestions for
expanded capabilities. The ABMS user manual is also posted under the Clinical Research
Associate tab on the ACCRU members’ website at www.accru.org.
Personnel Update
Jennifer Quam
Program Coordinator
Jennifer Quam
In December 2015, we said farewell to Jennifer Quam, program coordinator for
ACCRU. Jennifer has been an integral part of ACCRU and Mayo Clinic Cancer
Research Consortium (MCCRC), ACCRU’s predecessor, for the past nine years. We
thank Jennifer for her outstanding service and commitment and wish her the best in
her new role as associate project manager in Mayo Clinic Validation Support Services.
Megan Jordahl
Finance Analyst
Megan Jordahl, who has served as a regulatory affairs specialist for the past year, has
transitioned to a new role with ACCRU as a finance analyst. Megan’s responsibilities
will include addressing finance questions for members and sponsors and processing
site payments for clinical trial participation.
Megan Jordahl
Membership survey
Our members’ input and participation are critical to our research efforts. To ensure that we are
providing you with the best service, we ask that you complete a survey that will be sent via email
during second quarter 2016.
The survey will help us identify how we can serve you better. We look forward to your feedback.
11 ACCRU Connections | Spring 2016
ACCRU Research Coordinating Center staff
Bandel, Lorelei
Research Protocol Specialist
[email protected]
Ronken, Christine (Chris)
Administrative Assistant
[email protected]
Cheslock, Jolene
Administrative Assistant
[email protected]
Rossman, Susan (Sue)
Data Manager
[email protected]
Davis, Danielle
Research Protocol Specialist
[email protected]
Sagdalen, Desirae
Coordinator of Research Operations
[email protected]
Elsing, Alicia
Research Protocol Specialist
[email protected]
Shevlin, Tracee
Research Protocol Specialist
[email protected]
Harding, Kathleen (Kathy)
Administrative Assistant
[email protected]
Sleeper, Cindy
Finance Analyst
[email protected]
Hewlett, Michelle (Shelly)
Research Protocol Specialist
[email protected]
Sunnock, Leslie
Regulatory Affairs Specialist
[email protected]
Jordahl, Megan
Finance Analyst
[email protected]
Van Esch, Debra (Debbie)
Administrative Assistant, Supervisor
[email protected]
Kiefer, Elizabeth (Beth)
Chief Operations Officer
[email protected]
Zabel, Cristina
Quality Assurance Specialist
[email protected]
12 ACCRU Connections | Spring 2016
Contact ACCRU
ACCRU Research Coordinating Center
200 First Street SW
Rochester, Minnesota 55905
Phone: 507-538-7448
Fax: 507-538-0906
Website: accru.org
ACCRU YouTube Channel
By email:
•ACCRU Operations Office: [email protected]
• Finance Office: [email protected]
• Membership Roster Office: [email protected]
• Regulatory Affairs Office: [email protected]
ACCRU Connections Editorial Staff
Medical Editor
Editorial Board
Contributors
Axel Grothey, M.D.
Oncologist – Mayo Clinic
ACCRU Chair
Michelle Hewlett
Research Protocol Specialist
Alicia Elsing
Research Protocol Specialist
Managing Editor
Beth Kiefer
Chief Operations Officer
Sharon Rosen
Public Affairs
Desirae Sagdalen
Coordinator of Research Operations
Debbie Van Esch
Administrative Assistant, Supervisor
MC5724-01rev0316